Background: Early-onset myopathies show a wide spectrum of phenotypes and are
| INTRODUCTION
provides instructions for making a large protein, titin, that provides structural support, flexibility, and stability within the sarcomere (Bang et al., 2001; Kruger & Kotter, 2016) . Since titin plays a crucial role in the sarcomere, mutations in TTN may cause a wide spectrum of striated muscle diseases, including tibial muscular dystrophy, hereditary myopathy with early respiratory failure, and limb-girdle muscular dystrophy type 2J (LGMD2J) (Bang et al., 2001; Hackman et al., 2002; Pfeffer et al., 2014) .
The next-generation sequencing technique has enabled the elucidation of several genetic diseases associated with neuromuscular disease and is being rapidly implemented into routine clinical practice (Helman, Bonkowsky, & Vanderver, 2016) .
In this study, we describe a patient with two novel heterozygous TTN mutations presenting severe muscular weakness.
| Ethical compliance
We obtained written informed consent from the patient. This case report was approved by the Institutional Review Board of the Seoul National University Bundang Hospital, and it was conducted in accordance with the tenets of the Declaration of Helsinki (IRB number: B-1705-399-301).
| CASE REPORTS
A 10-year-old female patient visited the outpatient clinic of the Department of Rehabilitation Medicine for further evaluation of severe motor weakness, hypotonia, and poor sucking ability. There were no significant abnormal findings during the pre-and perinatal periods; however, motor development was delayed since birth. To date, she was never able to walk alone. On manual muscle test, she got a grade of 2 for proximal muscles and a grade of 3 for distal muscles in all upper and lower extremities. On the range of motion (ROM) test, the knee flexion contracture on the right side was 30°. No upper motor neuron sign was observed. Deep tendon reflexes were absent. She also showed suspicious tongue fasciculation and funnel chest. Cognitive function was normal and had no facial abnormalities. There was no history of delayed development, weakness or other neuromuscular abnormalities among the first-degree relatives of her father (one older sister and two older brothers) and mother (two younger sisters), except her younger sister (Figure 1a ). Her younger sister had similar symptoms, but with greater severity and respiratory failure. Creatine kinase (CK) levels were within normal limits. On X-ray studies, thoracolumbar scoliosis (the Cobb angle was 20°) and bilateral coxa valga (the caput-collum-diaphyseal (CCD) angles were 142°, 146°, right, and left side, respectively) were observed. Brain MRI showed no specific abnormality.
Nerve conduction studies showed normal findings (Table 1) . On electromyography, short-duration, small-amplitude motor unit action potential, and early recruitment patterns were observed in the involved proximal muscles, suggesting myopathy ( Table 2) .
The SMN study showed no abnormal findings. Genetic testing was performed using a targeted gene sequencing panel, analyzing 410 genes associated with genetic F I G U R E 1 (a) Pedigree of the family. Two different possible pathogenic variants in TTN, which were related with muscular dystrophy: (b) canonical splicing mutation in the intron 105 (c. 29963-1G>C) from the mother; and (c) frameshift and truncating mutation in the exon 339 (c.92812dup/p.Arg30938LysfsTer15) from the father neuromuscular diseases. Genomic DNA was extracted from the peripheral blood of the patient. Library preparation and target enrichment were performed using the hybridization capture method. Custom oligo design and synthesis were done by Agilent (USA). Massively parallel sequencing was performed using 2 × 150 bp in the paired end mode of NextSeq platform (Illumina, San Diego, CA). Sequence reads were aligned with the Burrow-Wheeler Aligner (version 0.7.12, MEM algorithm, MEM algorithm). After removing the duplicated reads with the Picard, local realignment and recalibration were performed using the Genome Analysis Tool Kit (GATK, version 3.5). Variants were annotated by Variant Effect Predictor and dbNSFP. Common variants with a minor allele frequency ≥ 1% were filtered out using public databases (i.e., 1,000 Genomes Project, Exome Variant Server, Exome Aggregation Consortium, and The Genome Aggregation Database). The average coverage depth was 182×, and 96.6% of the target bases were covered by more than 10 × sequence reads.
We found two different possible pathogenic variants in TTN (NM_001267550.1), which were related to muscular dystrophy: canonical splicing mutation in the intron 105 (c. 29963-1G > C) from the mother; and frameshift and truncating mutation in the exon 339 (c.92812dup/p. Arg30938LysfsTer15) from the father. All variants were confirmed by Sanger sequencing (Figure 1b,c) . The patient's parents were identified as heterozygous carriers for each variation occurring in trans. These novel variations have not been reported in the control databases, such as the 1,000 Genomes Project, Exome Aggregation Consortium, Exome Variant Server, dbVar, and the dbSNP Database.
For confirmation, muscle biopsy samples were taken from the vastus lateralis muscle. Immunohistochemical and histologic studies, including the electron microscopic exam, were performed. Histochemical evidence showed a specific atrophy of increased fiber size variability, frequent nuclear internalization, as well as the degeneration and regeneration of fibers with type I fiber predominance on muscle biopsy. On electron microscopy, we did not observe any nemaline body, centronuclear core, or multiminicore.
| DISCUSSION
The evidence presented here suggests that these frameshift and truncating mutations as well as canonical splicing mutations are the "pathogenic" variants, based on the American College of Medical Genetics and Genomics guidelines regarding the interpretation of sequence variations (PSV1 + PM2 + PP4) (Richards et al., 2015) . We also think that these two novel mutations may be the causative of the phenotypes in our patient.
Since the NGS technique enabled the sequencing of TTN, which is the longest coding sequence of any human gene, there is an increasing number of rising cases regarding the genetic diseases associated with TTN. A recent article published in JAMA neurology (Savarese et al., 2018) showed that a patient may be susceptible to the diagnosis of titinopathy, since these mutations are biallelic protein truncating variants.
Similar to previous studies that reported various phenotypes of TTN-related myopathy (Harris et al., 2017; Oates et al., 2018; Savarese et al., 2018) , our patient represented axial involvements, including neck weakness, scoliosis, funnel chest, muscle weakness (proximal > distal), limb contracture, and respiratory difficulties. The muscle biopsy result of the patient is increased fiber size variation and frequent internalized nuclei. These are two of the three main patterns that are found in the previous report on congenital titinopathy. The result of the fiber type analysis was degeneration and regeneration of fibers with type I fiber predominance, which is consistent with the result of the report (Oates et al., 2018) . Compared with patients reported in previous studies (Udd, Kaarianen, & Somer, 1991; Udd, Rapola, Nokelainen, Arikawa, & Somer, 1992) , our patient experienced extremely early onset. This might be due to "two-truncation" mutations in TTN, as suggested by a previous study (Harris et al., 2017) .
In conclusion, early-onset myopathy can be caused by various types of diseases, including genetic diseases. TTN mutation causes a wide spectrum of genetic diseases that present skeletal and/or cardiac myopathies; primary pathogenic gene mutation may determine these phenotypic variances that result in functional/structural damage in the sarcomere.
There are two limitations to this study. First, we were unable to examine the gene of the patient's sister. We were unable to perform blood tests because the patient's sister was on a ventilator due to severe respiratory failure and resided far from the hospital. Second, we were unable to further characterize our canonical splice site variant. As splice site mutation can result in the production of a near-normal sized protein product (Oates et al., 2018) , it is important to fully characterize our variant and see whether the splicing effect really causes truncation for a better understanding of the molecular causes of the disease. When we searched the HGMD professional database (2019.1), there was 18 splicing-related mutations, out of a total of 148 mutations, which were mostly truncating variants. Hence, together with our patient's symptoms, the result of examinations, and previously reported on HGMD professional database, we can highly suggest that our splicing variant is disease-causing mutation.
Since a massive evolution in genetic analyses was achieved, which enabled a comprehensive evaluation of titinopathy, we propose that unbiased genomic sequencing can be helpful in screening patients with early-onset myopathy.
